van 't Veer LJ - Search Results

1

A functional assay in yeast for the human estrogen receptor displays wild-type and variant estrogen receptor messenger RNAs present in breast carcinoma.

van Dijk MA, Floore AN, Kloppenborg KI, van 't Veer LJ. van Dijk MA, et al. Cancer Res. 1997 Aug 15;57(16):3478-85. Cancer Res. 1997. PMID: 9270016

2

cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines.

Kuppen PJ, Schuitemaker H, van 't Veer LJ, de Bruijn EA, van Oosterom AT, Schrier PI. Kuppen PJ, et al. Cancer Res. 1988 Jun 15;48(12):3355-9. Cancer Res. 1988. PMID: 2897238

3

A method to monitor mRNA levels in human breast tumor cells obtained by fine-needle aspiration.

de Lange MS, Top B, Lambrechts C, Maas RA, Peterse HL, Mooi WJ, van 't Veer LJ, Rodenhuis S. de Lange MS, et al. Diagn Mol Pathol. 1997 Dec;6(6):353-60. doi: 10.1097/00019606-199712000-00008. Diagn Mol Pathol. 1997. PMID: 9559296

4

ATM germline mutations in classical ataxia-telangiectasia patients in the Dutch population.

Broeks A, de Klein A, Floore AN, Muijtjens M, Kleijer WJ, Jaspers NG, van 't Veer LJ. Broeks A, et al. Hum Mutat. 1998;12(5):330-7. doi: 10.1002/(SICI)1098-1004(1998)12:5<330::AID-HUMU6>3.0.CO;2-H. Hum Mutat. 1998. PMID: 9792409

5

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.

Ligtenberg MJ, Hogervorst FB, Willems HW, Arts PJ, Brink G, Hageman S, Bosgoed EA, Van der Looij E, Rookus MA, Devilee P, Vos EM, Wigbout G, Struycken PM, Menko FH, Rutgers EJ, Hoefsloot EH, Mariman EC, Brunner HG, Van 't Veer LJ. Ligtenberg MJ, et al. Br J Cancer. 1999 Mar;79(9-10):1475-8. doi: 10.1038/sj.bjc.6690235. Br J Cancer. 1999. PMID: 10188893 Free PMC article.

6

Towards prediction and modulation of treatment response.

Bartelink H, Begg A, Martin JC, van Dijk M, van 't Veer L, van der Vaart P, Verheij M. Bartelink H, et al. Radiother Oncol. 1999 Jan;50(1):1-11. doi: 10.1016/s0167-8140(99)00009-2. Radiother Oncol. 1999. PMID: 10225551 Review.

7

Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells.

Lambrechts AC, Bosma AJ, Klaver SG, Top B, Perebolte L, van' t Veer LJ, Rodenhuis S. Lambrechts AC, et al. Breast Cancer Res Treat. 1999 Aug;56(3):219-31. doi: 10.1023/a:1006261731125. Breast Cancer Res Treat. 1999. PMID: 10573113

8

Differences in estrogen receptor alpha variant messenger RNAs between normal human breast tissue and primary breast carcinomas.

van Dijk MA, Hart AA, van 't Veer LJ. van Dijk MA, et al. Cancer Res. 2000 Feb 1;60(3):530-3. Cancer Res. 2000. PMID: 10676630

9

ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.

Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van 't Veer LJ. Broeks A, et al. Am J Hum Genet. 2000 Feb;66(2):494-500. doi: 10.1086/302746. Am J Hum Genet. 2000. PMID: 10677309 Free PMC article.

10

Translational research offers individually tailored treatments for cancer patients.

Bartelink H, Begg AC, Martin JC, van Dijk M, Moonen L, van 't Veer LJ, Van de Vaart P, Verheij M. Bartelink H, et al. Cancer J Sci Am. 2000 Jan-Feb;6(1):2-10. Cancer J Sci Am. 2000. PMID: 10696731 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

401 results

Search Page

Filters